Interpace Biosciences Valuation
Is IDXG undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of IDXG when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: IDXG ($2.68) is trading below our estimate of fair value ($84.45)
Significantly Below Fair Value: IDXG is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for IDXG?
Key metric: As IDXG is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is IDXG's PE Ratio? | |
|---|---|
| PE Ratio | 2.4x |
| Earnings | US$4.89m |
| Market Cap | US$11.77m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 1.4x |
| Enterprise Value/EBITDA | 9.6x |
| PEG Ratio | n/a |
Price to Earnings Ratio vs Peers
How does IDXG's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 69.5x | ||
AMS American Shared Hospital Services | 4.9x | n/a | US$19.1m |
NIVF NewGenIvf Group | 46.4x | n/a | US$5.8m |
AONC American Oncology Network | 97.5x | n/a | US$175.4m |
INFU InfuSystem Holdings | 129.2x | 66.5% | US$193.5m |
IDXG Interpace Biosciences | 2.4x | n/a | US$11.8m |
Price-To-Earnings vs Peers: IDXG is good value based on its Price-To-Earnings Ratio (2.4x) compared to the peer average (69.5x).
Price to Earnings Ratio vs Industry
How does IDXG's PE Ratio compare vs other companies in the US Healthcare Industry?
| 5 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| Industry Avg. | 25.8x | 20.8% | |
IDXG Interpace Biosciences | 2.4x | n/a | US$11.77m |
THC Tenet Healthcare | 4.6x | -39.2% | US$14.58b |
NEUE NeueHealth | 1.5x | n/a | US$40.77m |
| 5 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
| Industry Avg. | 25.8x | 20.8% | |
IDXG Interpace Biosciences | 2.4x | n/a | US$11.77m |
Price-To-Earnings vs Industry: IDXG is good value based on its Price-To-Earnings Ratio (2.4x) compared to the US Healthcare industry average (25.2x).
Price to Earnings Ratio vs Fair Ratio
What is IDXG's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 2.4x |
| Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate IDXG's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Centene
US$29.2b
Operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States.
CNC
US$59.10
7D
1.8%
1Y
-20.4%
Elevance Health
US$91.4b
Operates as a health benefits company in the United States.
ELV
US$397.48
7D
-3.3%
1Y
-17.2%
CVS Health
US$70.2b
Provides health solutions in the United States.
CVS
US$56.83
7D
4.7%
1Y
-17.8%